SpineGuard specializes in the design, development, and marketing of medical devices intended to improve the safety of spinal surgery. The group is developing DSG® digital technology for real-time surgical guidance without X-rays to improve the safety and simplify the placement of bone implants, pedicle screws, and "smart" drills. SpineGuard is extending the applications of its DSG® technology to anterior scoliosis treatment, sacroiliac joint fusion, and dental implantology.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

08/10 Sales and Revenue Release - Q3 2026

More about the company

Market Cap	8.72M 9.81M 8.14M 7.42M 13.99M 943M 14.12M 98.48M 38.16M 482M 36.84M 36.04M 1.55B	P/E 2024	-3.63x	P/E 2025	-3.37x
Enterprise Value	8.45M 9.51M 7.89M 7.19M 13.56M 915M 13.69M 95.48M 37M 468M 35.72M 34.95M 1.5B	EV / Sales 2024	2.94x	EV / Sales 2025	2.33x
Free-Float	97.13%	Yield 2024 *	-	Yield 2025	-

08:58pm	Weekly earnings calendar: PepsiCo kicks off the quarterly marathon
10/09	SpineGuard SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
10/09	SpineGuard says it can cover its funding needs through the second quarter of 2027
05/09	Weekly earnings calendar: Oracle vs Adobe, a battle of old hands
25/08	SpineGuard Wins US Patent for Robotic Ultrasound Technology	MT
25/08	Spineguard Obtains New U.S. Patent for Innovative Ultrasound Technology Designed to Determine Entry Point and Pedicular Drilling Trajectory	CI
25/08	SpineGuard lands a new US patent in spinal guidance
28/07	SpineGuard, Omnia Medical Obtain New US Patent for Dynamic Surgical Guidance Technology	MT
28/07	SpineGuard And Omnia Medical Obtain Notice Of Allowance For U.S. Patent Application For Innovative Application Of DSG Technology To Sacroiliac Joint Fusion	CI
28/07	SpineGuard Secures a New Patent in the United States
09/07	Spineguard SA Reports Unaudited Consolidated Revenue Results for the Second Quarter and First Half of 2026	CI
08/07	Zonebourse earnings calendar for company results: July 8, 2026
27/05	SpineGuard Secures Three Patent Applications in US	MT

10/09	SpineGuard Reports 2026 Half-Year Results	BU
25/08	SpineGuard Obtains a New U.S. Patent for Its Innovative Ultrasound Technology Designed to Determine the Entry Point and Pedicular Drilling Trajectory	BU
28/07	SpineGuard and Omnia Medical Obtain a New U.S. Patent for Their Innovative Application of DSG Technology to Sacroiliac Joint Fusion	BU
09/07	SpineGuard Announces its H1 2026 Revenue	BU
27/05	SpineGuard Obtains Three New Patents for Full Protection in the U.S. of Its Innovative Solutions Integrating DSG Technology	BU

05/10	Agenda des résultats de la semaine : PepsiCo lance le marathon trimestriel
03/10	Agenda Zonebourse des résultats de sociétés : semaine du 5 au 9 octobre 2026
10/09	SpineGuard estime pouvoir couvrir ses besoins de financement jusqu'au deuxième trimestre 2027
10/09	SpineGuard annonce ses résultats semestriels 2026
05/09	Agenda Zonebourse des résultats de sociétés : semaine du 7 au 11 septembre 2026

Manager	Title	Age	Since
Pierre Jérôme CEO	Chief Executive Officer	-	15/02/2020
Anne-Charlotte Millard DFI	Director of Finance/CFO	-	01/01/2009
Thibault Chandanson CTO	Chief Tech/Sci/R&D Officer	-	01/09/2019

SpineGuard Stock Other OTC

Stocks

Medical Equipment, Supplies & Distribution

Valuation: SpineGuard

Latest news: SpineGuard

Analysts' recommendations: SpineGuard

Press Releases: SpineGuard

News in other languages: SpineGuard

Managers and Directors: SpineGuard

Medical Equipment

Financials

Company Profile

Director	Title	Age	Since
Stéphane Bette BRD	Director/Board Member	-	16/01/2009
Maurice Bourlion BRD	Director/Board Member	-	02/07/2009
Pierre Jérôme CHM	Chairman	-	01/03/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPINEGUARD	-.--%	-.--%	-	-	9.81M
ABBOTT LABORATORIES	+0.84%	-3.74%	-27.56%	+1.93%	169B
MEDTRONIC PLC	-0.07%	-2.55%	-11.59%	+13.26%	110B
STRYKER CORPORATION	+0.90%	+1.13%	-25.66%	+3.47%	106B
ESSILORLUXOTTICA	+1.51%	-0.82%	-47.52%	-11.10%	73.87B
CENCORA, INC.	-0.24%	+0.69%	+2.08%	+69.19%	58.98B
HOYA CORPORATION	+1.32%	+3.86%	+8.58%	+61.88%	51.28B
BECTON, DICKINSON AND COMPANY	-0.71%	-3.82%	-8.68%	-31.93%	48.16B
IDEXX LABORATORIES, INC.	+0.12%	-0.17%	-17.87%	+19.66%	40.84B
DEXCOM, INC.	-1.01%	-1.45%	+27.31%	-2.67%	32.21B
Average	+0.05%	-0.86%	-11.21%	+13.74%	76.69B
Weighted average by Cap.	+0.06%	-1.30%	-17.18%	+11.26%

	2024	2025
Net sales	4.65M 5.23M 4.34M 3.95M 7.46M 503M 7.53M 52.5M 20.34M 257M 19.64M 19.21M 825M	3.76M 4.23M 3.51M 3.2M 6.03M 407M 6.08M 42.44M 16.44M 208M 15.88M 15.53M 667M
Net income	-3.08M -3.47M -2.88M -2.62M -4.94M -333M -4.99M -34.81M -13.49M -170M -13.02M -12.74M -547M	-2.07M -2.33M -1.93M -1.76M -3.32M -224M -3.35M -23.35M -9.05M -114M -8.74M -8.55M -367M
Net Debt	1.82M 2.05M 1.7M 1.55M 2.92M 197M 2.95M 20.54M 7.96M 101M 7.69M 7.52M 323M	-265K -299K -248K -226K -426K -28.71M -430K -3M -1.16M -14.68M -1.12M -1.1M -47.11M